Guardant Health, Inc. $GH Shares Purchased by HighVista Strategies LLC

HighVista Strategies LLC boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 128.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,583 shares of the company’s stock after acquiring an additional 36,318 shares during the quarter. Guardant Health accounts for 1.0% of HighVista Strategies LLC’s holdings, making the stock its 27th largest position. HighVista Strategies LLC’s holdings in Guardant Health were worth $4,035,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Emerald Advisers LLC lifted its stake in shares of Guardant Health by 24.8% in the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after purchasing an additional 173,281 shares during the period. Knights of Columbus Asset Advisors LLC acquired a new position in shares of Guardant Health in the third quarter worth about $1,554,000. Edgestream Partners L.P. boosted its stake in shares of Guardant Health by 147.3% during the 2nd quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock worth $2,629,000 after acquiring an additional 30,094 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Guardant Health by 54.4% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after acquiring an additional 106,263 shares during the period. Finally, State of Wyoming acquired a new stake in shares of Guardant Health during the 2nd quarter valued at about $567,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Medina Manuel Hidalgo sold 1,300 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $91.54, for a total value of $119,002.00. Following the transaction, the director owned 1,193 shares of the company’s stock, valued at $109,207.22. This represents a 52.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Terilyn J. Monroe sold 10,031 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $112.08, for a total value of $1,124,274.48. Following the completion of the sale, the insider owned 20,990 shares in the company, valued at approximately $2,352,559.20. This represents a 32.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 20,018 shares of company stock valued at $2,232,911 in the last quarter. 6.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Leerink Partners upped their price target on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. TD Cowen boosted their price objective on Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Raymond James Financial reiterated an “outperform” rating and set a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. Finally, JPMorgan Chase & Co. raised their target price on Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Twenty-one analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.57.

Guardant Health Stock Up 1.7%

Shares of GH opened at $85.49 on Monday. The company has a market cap of $11.21 billion, a P/E ratio of -25.83 and a beta of 1.67. Guardant Health, Inc. has a fifty-two week low of $36.36 and a fifty-two week high of $120.74. The firm’s 50 day moving average price is $103.92 and its 200 day moving average price is $90.02.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. The firm’s quarterly revenue was up 39.4% on a year-over-year basis. During the same period last year, the business posted ($0.62) EPS. Research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.